324 related articles for article (PubMed ID: 21456524)
1. Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.
Strader CR; Pearce CJ; Oberlies NH
J Nat Prod; 2011 Apr; 74(4):900-7. PubMed ID: 21456524
[TBL] [Abstract][Full Text] [Related]
2. Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
Chiba K; Adachi K
Future Med Chem; 2012 Apr; 4(6):771-81. PubMed ID: 22530640
[TBL] [Abstract][Full Text] [Related]
3. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
[TBL] [Abstract][Full Text] [Related]
4. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.
Chiba K
Pharmacol Ther; 2005 Dec; 108(3):308-19. PubMed ID: 15951022
[TBL] [Abstract][Full Text] [Related]
5. [Basic mechanisms of action of fingolimod in relation to multiple sclerosis].
García-Merino JA; Sánchez AJ
Rev Neurol; 2012 Jul; 55(1):31-7. PubMed ID: 22718407
[TBL] [Abstract][Full Text] [Related]
6. Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy.
Ingwersen J; Aktas O; Kuery P; Kieseier B; Boyko A; Hartung HP
Clin Immunol; 2012 Jan; 142(1):15-24. PubMed ID: 21669553
[TBL] [Abstract][Full Text] [Related]
7. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
Lee CW; Choi JW; Chun J
Arch Pharm Res; 2010 Oct; 33(10):1567-74. PubMed ID: 21052934
[TBL] [Abstract][Full Text] [Related]
8. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
Dev KK; Mullershausen F; Mattes H; Kuhn RR; Bilbe G; Hoyer D; Mir A
Pharmacol Ther; 2008 Jan; 117(1):77-93. PubMed ID: 17961662
[TBL] [Abstract][Full Text] [Related]
9. Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus.
Chiba K; Matsuyuki H; Maeda Y; Sugahara K
Cell Mol Immunol; 2006 Feb; 3(1):11-9. PubMed ID: 16549044
[TBL] [Abstract][Full Text] [Related]
10. Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: a case of xenobiotic biotransformation following endogenous metabolic pathways.
Zollinger M; Gschwind HP; Jin Y; Sayer C; Zécri F; Hartmann S
Drug Metab Dispos; 2011 Feb; 39(2):199-207. PubMed ID: 21045200
[TBL] [Abstract][Full Text] [Related]
11. [Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism].
Tar L; Vécsei L
Ideggyogy Sz; 2012 Mar; 65(3-4):83-100. PubMed ID: 23136726
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of 4(5)-phenylimidazole-based analogues of sphingosine-1-phosphate and FTY720: discovery of potent S1P1 receptor agonists.
Clemens JJ; Davis MD; Lynch KR; Macdonald TL
Bioorg Med Chem Lett; 2005 Aug; 15(15):3568-72. PubMed ID: 15982878
[TBL] [Abstract][Full Text] [Related]
13. Antibody against a novel, myriocin (ISP-I)-based immunosuppressant, FTY720.
Fujita T; Matsumoto N; Uchida S; Kohno T; Shimizu T; Hirose R; Yanada K; Kurio W; Watabe K
Bioorg Med Chem Lett; 2000 Feb; 10(4):337-9. PubMed ID: 10714494
[TBL] [Abstract][Full Text] [Related]
14. Fingolimod: a novel immunosuppressant for multiple sclerosis.
Brown BA; Kantesaria PP; McDevitt LM
Ann Pharmacother; 2007 Oct; 41(10):1660-8. PubMed ID: 17785617
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS.
Kowarik MC; Pellkofer HL; Cepok S; Korn T; Kümpfel T; Buck D; Hohlfeld R; Berthele A; Hemmer B
Neurology; 2011 Apr; 76(14):1214-21. PubMed ID: 21464424
[TBL] [Abstract][Full Text] [Related]
16. [Fingolimod - a new immunomodulator].
Friedrich FW; Eschenhagen T
Dtsch Med Wochenschr; 2009 Oct; 134(42):2127-31. PubMed ID: 19809964
[TBL] [Abstract][Full Text] [Related]
17. Fingolimod. Mitsubishi Pharma/Novartis.
Dumont FJ
IDrugs; 2005 Mar; 8(3):236-53. PubMed ID: 15772896
[TBL] [Abstract][Full Text] [Related]
18. [Research progress of the selective sphingosine-1-phosphate receptor 1 agonists].
Tian YL; Jin J; Wang XJ
Yao Xue Xue Bao; 2012 Jan; 47(1):7-17. PubMed ID: 22493799
[TBL] [Abstract][Full Text] [Related]
19. Discovery of fingolimod based on the chemical modification of a natural product from the fungus, Isaria sinclairii.
Chiba K
J Antibiot (Tokyo); 2020 Oct; 73(10):666-678. PubMed ID: 32681100
[TBL] [Abstract][Full Text] [Related]
20. FTY720: from bench to bedside.
Kahan BD
Transplant Proc; 2004 Mar; 36(2 Suppl):531S-543S. PubMed ID: 15041402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
